Moving on from a costly Phase II setback for its lead drug, Ardelyx is looking to go it alone without AstraZeneca, buying out its former partner and pressing forward into late-stage development.
Japan's Eisai, Shinogi and Takeda Pharmaceutical have teamed up with U.K.-based AstraZeneca on a broad R&D effort to find treatments for insect-borne parasitic diseases Chagas and leishmaniasis.
Bristol-Myers Squibb is the leader right now in immuno-oncology and checkpoint inhibitors and it clearly is willing to get aggressive about defending that early edge. In a move that shows just how competitive this blockbuster field has become, the big biotech wants to force one of its ex-R&D leaders in I/O to sit out the next year rather than go to work for a major league rival.
With a new crop of cancer immunotherapy drugs that offer the hope of battling forms of cancer previously thought untreatable, researchers and physicians are looking for tests that can better pinpoint which patients respond to each of the treatments.
Definiens introduced a suite of services to help companies gather data from tissue samples and use the resource to identify potential companion diagnostics.
AstraZeneca Pharma India has signed up Dr. Reddy's Laboratories to distribute its diabetes medicines Riax and Riax-M in India as domestic and foreign companies look for advantages in a crucial and sharply competitive market where generic activity is on the rise.
Over the weekend, Clovis Oncology took another big step toward its near-term goal of launching commercial operations, with plans to take pharma giant AstraZeneca head-on with two key franchise showdowns. The Boulder, CO-based biotech posted positive data from a mid-stage study of its ovarian cancer drug rucaparib at ASCO, while adding new--though less impressive--data to back up its lead drug for non-small cell lung cancer.
AstraZeneca believes the brightest future for its top oncology prospect will come through collaboration, recruiting Eli Lilly to its growing ranks of partners with eyes on kicking off a combination cancer trial.
One year ago, Pfizer finally bowed out of the fight to buy AstraZeneca. The hostile bid was, well, quite hostile. And ever since, both companies have operated in the shadow of that failed deal.
When you're targeting an under-the-radar malady that hasn't traditionally been treated with prescription drugs, it's up to marketers to get the word out and deliver on sales. And that's why AstraZeneca and Daiichi Sankyo, whose Movantik launched earlier this year, are bringing a 6-time Olympic medalist on board to talk about opioid-induced constipation (OIC).